Key result
Nasal heat shock protein-65 reduces atherosclerotic plaque size and macrophage infiltration in mice.
Why the study?
Autoimmunity to heat shock proteins is involved in the progression of atherosclerosis, and mucosal administration of autoantigens decreases inflammation in other models of autoimmunity, prompting evaluation of nasal or oral HSP-65 administration on atherosclerotic lesion formation.
Does mucosal (nasal or oral) administration of mycobacterial HSP-65 reduce atherosclerotic lesion formation and inflammation in LDL receptor-deficient mice on a high-cholesterol diet?
Does mucosal (nasal or oral) administration of mycobacterial HSP-65 reduce atherosclerotic lesion formation and inflammation in LDL receptor-deficient mice on a high-cholesterol diet?
Nasal vaccination with mycobacterial HSP-65 reduces aortic arch atherosclerosis and plaque inflammation in hypercholesterolemic mice, suggesting a potential novel immunologic strategy for atherosclerosis.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for nasal HSP-65 immunotherapy in atherosclerosis; human trials required before clinical consideration.
BACKGROUND: Increasing evidence supports the involvement of inflammation and immunity in atherogenesis as well as the role of autoimmunity to heat shock proteins (HSPs) in the progression of atherosclerosis. Mucosal administration of autoantigens decreases organ-specific inflammation and disease in several models of autoimmunity (diabetes, arthritis, and encephalomyelitis) and is also being tested in human clinical trials. METHODS AND RESULTS: We examined the effect of nasal or oral administration of mycobacterial HSP-65 on atherosclerotic lesion formation in mice lacking the receptor for LDL that were maintained on a high-cholesterol diet. Animals were nasally or orally treated for 1 week with HSP-65, and a high-cholesterol diet was started after the last treatment. The mice were mucosally treated once a week for 8 or 12 weeks, at which time pathological analysis was performed. We found a significant decrease in the size of atherosclerotic plaques, a reduction in macrophage-positive area in the aortic arch, increased interleukin-10 expression, and a reduced number of T cells in nasally treated animals compared with control animals. A similar trend was observed in orally treated mice, but it was not significant. CONCLUSIONS: Our results demonstrate that nasal vaccination with HSP reduces the inflammatory process associated with atherosclerosis and provides a new immunologic approach for the treatment of atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Maron et al. (2002) studied Atherosclerosis. Nasal or oral administration of mycobacterial heat shock protein-65 vs. Control animals was evaluated on Size of atherosclerotic plaques. Nasal administration of heat shock protein-65 significantly decreased atherosclerotic plaque size and macrophage-positive area in LDL receptor-deficient mice compared with controls.
Synapse has enriched 10 related papers. Consider them for comparative context: